Artificially Cloaked Viral Nanovaccine for Cancer Immunotherapy

Visa fullständig post



Fusciello , M , Fontana , F , Tähtinen , S , Capasso , C , Feola , S , da Silva Lopes Martins , B , Chiaro , J , Peltonen , K , Ylösmäki , L , Ylösmäki , E , Hamdan Hissaoui , F , Kari , O K , Ndika , J , Alenius , H , Urtti , A , Hirvonen , J T , Santos , H A & Cerullo , V 2019 , ' Artificially Cloaked Viral Nanovaccine for Cancer Immunotherapy ' , Nature Communications , vol. 10 , 5747 .

Titel: Artificially Cloaked Viral Nanovaccine for Cancer Immunotherapy
Författare: Fusciello, Manlio; Fontana, Flavia; Tähtinen, Siri; Capasso, Cristian; Feola, Sara; da Silva Lopes Martins, Beatriz; Chiaro, Jacopo; Peltonen, Karita; Ylösmäki, Leena; Ylösmäki, Erkko; Hamdan Hissaoui, Firas; Kari, Otto K.; Ndika, Joseph; Alenius, Harri; Urtti, Arto; Hirvonen, Jouni T.; Santos, Hélder A.; Cerullo, Vincenzo
Upphovmannens organisation: ImmunoViroTherapy Lab
Division of Pharmaceutical Biosciences
Drug Research Program
Digital Precision Cancer Medicine (iCAN)
Nanomedicines and Biomedical Engineering
Division of Pharmaceutical Chemistry and Technology
Drug Delivery Unit
Department of Bacteriology and Immunology
HUMI - Human Microbiome Research
Drug Delivery
Jouni Hirvonen / Principal Investigator
Helsinki One Health (HOH)
Helsinki Institute of Life Science HiLIFE
Datum: 2019-12-17
Språk: eng
Sidantal: 13
Tillhör serie: Nature Communications
ISSN: 2041-1723
Permanenta länken (URI):
Abstrakt: Virus-based cancer vaccines are nowadays considered an interesting approach in the field of cancer immunotherapy, despite the observation that the majority of the immune responses they elicit are against the virus and not against the tumor. In contrast, targeting tumor associated antigens is effective, however the identification of these antigens remains challenging. Here, we describe ExtraCRAd, a multi-vaccination strategy focused on an oncolytic virus artificially wrapped with tumor cancer membranes carrying tumor antigens. We demonstrate that ExtraCRAd displays increased infectivity and oncolytic effect in vitro and in vivo. We show that this nanoparticle platform controls the growth of aggressive melanoma and lung tumors in vivo both in preventive and therapeutic setting, creating a highly specific anti-cancer immune response. In conclusion, ExtraCRAd might serve as the next generation of personalized cancer vaccines with enhanced features over standard vaccination regimens, representing an alternative way to target cancer.
biohybrid nanoparticles
oncolytic vaccines
oncolytic virus
317 Pharmacy
318 Medical biotechnology
Referentgranskad: Ja
Licens: cc_by
Användningsbegränsning: openAccess
Parallelpublicerad version: publishedVersion

Filer under denna titel

Totalt antal nerladdningar: Laddar...

Filer Storlek Format Granska
s41467_019_13744_8.pdf 1.701Mb PDF Granska/Öppna

Detta dokument registreras i samling:

Visa fullständig post